Cyclic Peptides

A cyclic peptide is a peptide chain whose ends, or two distant positions along it, are joined so that it forms a ring[1]. The link that closes the ring can be an ordinary peptide bond, but also an ester, a disulfide bridge or another type of bond[2]. Many hormones, toxins and antibiotics are cyclic, and so are some well-known medicines, among them oxytocin, vancomycin and cyclosporine[1].

Closing the ring changes how a peptide behaves: it becomes less floppy, harder to digest and, in some cases, able to cross cell membranes. Most of the interest in cyclic peptides, from natural antibiotics to new drugs, comes from these three changes.

Cyclic peptides at a glance
Approved drugsMore than 40 by 2024, with about one new cyclic peptide drug a year over the last three decades
Typical useInjected, acting on targets outside the cell; only a few are taken by mouth
Main advantagesTighter and more selective binding, resistance to protein-digesting enzymes, sometimes the ability to cross membranes
Largest screening librariesMore than 1013 different cyclic peptides

Why close the ring

A short linear peptide in water is floppy. It keeps switching between a large number of shapes, and only a few of them fit its target[3]. When it binds, it has to freeze into one shape, and that loss of freedom costs binding energy. If the ring holds the chain close to the shape its target needs, less is lost on binding; a ring closed in the wrong place can instead hold it in the wrong shape. This entropic effect is the usual explanation of why cyclic peptides tend to bind more tightly and more selectively than linear ones[1][3]. In screens of large peptide libraries, cyclic peptides generally outperform linear members[1].

A ring is also harder to digest. Peptides are natural food for proteases, and the human genome encodes more than 550 of them[3]. Exopeptidases nibble from free ends, which a head-to-tail ring does not have (a ring closed by a disulfide bridge may keep them), and a rigid ring often cannot fit into the active site of the enzymes that cut inside a chain. Cyclic peptides are therefore usually more resistant to both kinds[1][4].

Finally, some cyclic peptides can cross cell membranes, which linear peptides of the same size rarely do. Cyclosporine is the classic case: an 11-residue cyclic peptide of 1203 Da that enters cells and works when swallowed[1]. How it manages this is explained in the section on membranes.

Types of ring

IUPAC divides cyclic peptides by the bonds in the ring[2]:

  • Homodetic cyclic peptides have a ring made only of normal peptide bonds, as when the N-terminus is joined to the C-terminus ("head to tail"). Cyclosporine and tyrocidine are examples. The smallest members are the 2,5-diketopiperazines, the cyclic dipeptides described on the dipeptides page.
  • Heterodetic cyclic peptides are built from amino acids, but at least one bond in the ring is something else: an isopeptide bond through a side chain, a disulfide bridge, an ester or another linkage.

When an ester replaces one of the amide bonds, the compound is also called a depsipeptide[2]. Many natural cyclic peptides combine several kinds of link, and some have two or more rings. The main options and how they change the mass of the peptide:

Ring closed byLinkMass change, DaExamples
Head to tailPeptide bond between the two termini−18.011Cyclosporine, tyrocidine
DisulfideCys–S–S–Cys−2.016Oxytocin, vasopressin, somatostatin
Side-chain lactamLys amine to Asp or Glu carboxyl−18.011Designed analogues
Lactone (ester)Thr, Ser or Tyr hydroxyl to a carboxyl−18.011Daptomycin, romidepsin
Side-chain cross-linksAryl–aryl and aryl ether bondsvariesVancomycin
Hydrocarbon stapleCarbon chain between two unnatural residuesvariesStapled α-helices

Mass changes are monoisotopic, relative to the open-chain peptide. Examples from Ji et al.[1], Walsh[5] and Schafmeister et al.[6]

Whether a disulfide-closed peptide such as oxytocin counts as "cyclic" depends on the definition. It contains a ring, so it is a heterodetic cyclic peptide in the IUPAC sense, and it is usually listed among cyclic peptide drugs[1]. But its backbone is not closed: it keeps a free N-terminus and a short linear tail, and the ring exists only because of the disulfide bridge.

Mass and charge

Closing a ring with a peptide bond, a lactam or an ester releases one water, so the cyclic peptide is 18.011 Da lighter (monoisotopic) than its linear precursor. For the pentapeptide RGDFV, for example, the linear form has a monoisotopic mass of 592.297 Da and the head-to-tail cyclic form 574.286 Da. A disulfide bridge removes only two hydrogens, 2.016 Da. The peptide calculator handles disulfide bridges directly; for a head-to-tail ring, subtract 18.011 Da from the mass it gives for the linear chain.

A head-to-tail ring also loses its free amino and carboxyl ends. Its charge and isoelectric point then depend only on the side chains.

Cyclic peptides in nature

A large share of natural cyclic peptides are not made by the ribosome. Bacteria and fungi assemble them on nonribosomal peptide synthetases, huge enzymes built like assembly lines, one module per amino acid. These can use building blocks the ribosome cannot, and many natural cyclic peptides contain non-standard amino acids as a result[1][5]. The ring is usually closed at the end of the line by a thioesterase domain, which can join the chain head to tail, as in the antibiotic tyrocidine, or through a side-chain hydroxyl, as in daptomycin[5]. In vancomycin, further enzymes add three cross-links between aromatic side chains, which make the molecule rigid[5]. Other cyclic peptides are made by the ribosome as ordinary chains and then cyclised and modified by dedicated enzymes[1].

PeptideSourceRingKnown for
CyclosporineFungusHead to tail, 11 residues, 7 N-methylatedImmunosuppressant; taken by mouth
VancomycinAmycolatopsis orientalisHeptapeptide with three side-chain cross-linksAntibiotic for severe Gram-positive infections
DaptomycinStreptomycesLactone ring plus a lipid tailAntibiotic that disrupts bacterial membranes
TyrocidineBacteriaHead to tail, 10 residuesAntibiotic
NisinLactococcus lactisThioether (lanthionine) ringsFood preservative, E234 on labels
Sunflower trypsin inhibitor (SFTI-1)Sunflower seedsHead to tail plus a disulfideEnzyme inhibitor; a scaffold for drug design
Microcystin-LRCyanobacteriaCyclic, with unusual amino acidsToxin in algal blooms
OxytocinHumans and other mammalsDisulfide ring, 9 residuesHormone; used to induce labour

From Ji et al.[1] and Walsh[5].

Plants and animals also make small, very stable proteins held together by several disulfide bonds. In the cyclotides of plants the backbone is also closed head to tail; in the conotoxins of cone snails it is usually linear, and the disulfide bonds alone hold the fold. Both are stable enough to be used as frameworks into which other active peptide sequences can be grafted[7]. One conotoxin, ziconotide, a peptide of 25 amino acids, is itself a drug for neuropathic pain, but it has to be injected into the fluid around the spinal cord. An engineered version of another conotoxin, closed head to tail, worked when given by mouth in rats[7].

Making cyclic peptides

In the laboratory, the linear precursor is usually built by solid-phase synthesis, and the ring is closed in a separate step. The difficulty is that the two ends of one molecule must find each other before they find another molecule. Otherwise chains join into dimers and longer oligomers. Ring closure is therefore done at high dilution, typically below 1 mM[4]. Another option is to close the ring while the peptide is still on the resin, anchored through a side chain such as that of aspartic or glutamic acid, so that the chains are kept apart[4].

Ring size matters. Head-to-tail closure is usually easy for peptides of more than seven amino acids, but small rings are strained. Attempts to close natural cyclic tetra- and pentapeptides head to tail have often given mainly cyclic dimers and trimers, or a product in which the last residue has flipped to its D-form[4]. Residues that favour turns help to bring the ends together. Proline is the strongest turn-former, and D-amino acids placed in an all-L chain have a similar effect[4].

Cyclic peptides as drugs

Over the last three decades about one cyclic peptide drug a year has been approved, and by 2024 there were more than 40[1]. Many are natural peptides or derivatives of them:

  • Hormone analogues. Somatostatin, a 14-residue hormone, was shortened to the 8-residue cyclic peptide octreotide, approved in 1988 and later a billion-dollar drug; lanreotide and pasireotide followed in 2007 and 2012. Desmopressin is a more stable analogue of vasopressin. Bremelanotide (2019) and setmelanotide (2020) act on the melanocortin-4 receptor[1].
  • Antibiotics. Vancomycin and its semi-synthetic relatives telavancin, dalbavancin and oritavancin; daptomycin, approved in 2003[1].
  • Antifungals. Caspofungin, micafungin and anidulafungin, cyclic lipopeptides that block the synthesis of the fungal cell wall[1].
  • Drugs acting inside cells. Cyclosporine, the anticancer agent romidepsin and several hepatitis C protease inhibitors[1].

Most cyclic peptide drugs are large, with ten or more amino acids, act on targets outside the cell and are given by injection[1]. Typical macrocycles found by modern screening weigh around 1800 Da, far above the 500 Da limit of the "rule of five" used to predict whether a small molecule will work by mouth[3]. Their size is also an advantage: it lets them bind the broad, flat surfaces where two proteins meet, which small molecules struggle to block[3].

Getting through membranes

Cyclosporine shows how a large peptide can still cross a membrane. Seven of its eleven amide bonds carry a methyl group on the nitrogen, and the remaining four N–H groups form hydrogen bonds inside the ring, so its polar groups are hidden when it enters the fatty interior of a membrane. Opened into a linear chain, it loses much of this ability[1]. N-methylation and internal hydrogen bonding are now used on purpose to design permeable cyclic peptides[1]. Still, few cyclic peptide drugs are taken by mouth. Desmopressin is one of them: less than 1% of an oral dose reaches the blood, but the peptide is potent enough to work anyway. Among newer candidates, a tricyclic peptide from Merck that blocks PCSK9, a regulator of blood cholesterol, reached 2.9% in monkeys with a permeation enhancer[1].

Stapled peptides

The ring does not have to close the whole chain. In a stapled peptide it links two side chains of a helix, which applies the idea of the first section, holding a chain in its binding shape, to a single turn or two. α-Helices are common at the interfaces where proteins bind each other, but a short peptide cut out of such a helix is often only partly helical in water[3][6]. Introducing two unnatural amino acids with olefin side chains at positions i and i+4, or i and i+7, one or two turns apart, and joining them by ring-closing metathesis "staples" the helix. The method was introduced in 2000 to increase both helicity and metabolic stability[6].

Screening huge libraries

Instead of starting from a natural product, cyclic peptide drugs can now be found by screening. Phage display, introduced in the late 1980s, and mRNA display, about a decade later, link each peptide to the genetic information that encodes it[1]. With mRNA display and a reprogrammed genetic code, libraries of more than 1013 cyclic peptides, including non-standard amino acids, can be screened against a target in hours to days[8]. One such programme produced LUNA18, an N-methylated cyclic peptide against the cancer target KRAS with an oral bioavailability of 21–47% in animals[1].

In short

  • A cyclic peptide is a peptide closed into a ring, by a peptide bond (homodetic) or by an ester, disulfide or other link (heterodetic).
  • The ring makes the peptide less floppy, which helps it bind more tightly, and makes it harder for proteases to cut.
  • Nature makes many cyclic peptides, often on enzyme assembly lines rather than ribosomes; cyclosporine, vancomycin and daptomycin all come from microbes.
  • More than 40 cyclic peptide drugs are approved. Most are injected; cyclosporine shows that N-methylation and hidden hydrogen bonds can make a large peptide work by mouth.

References

  1. Ji X, Nielsen AL, Heinis C (2024). Cyclic peptides for drug development. Angewandte Chemie International Edition 63:e202308251. DOI: 10.1002/anie.202308251
  2. IUPAC-IUB Joint Commission on Biochemical Nomenclature (1984). Nomenclature and symbolism for amino acids and peptides (Recommendations 1983). Pure and Applied Chemistry 56:595–624. DOI: 10.1351/pac198456050595
  3. Vinogradov AA, Yin Y, Suga H (2019). Macrocyclic peptides as drug candidates: recent progress and remaining challenges. Journal of the American Chemical Society 141:4167–4181. DOI: 10.1021/jacs.8b13178
  4. White CJ, Yudin AK (2011). Contemporary strategies for peptide macrocyclization. Nature Chemistry 3:509–524. DOI: 10.1038/nchem.1062
  5. Walsh CT (2004). Polyketide and nonribosomal peptide antibiotics: modularity and versatility. Science 303:1805–1810. DOI: 10.1126/science.1094318
  6. Schafmeister CE, Po J, Verdine GL (2000). An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides. Journal of the American Chemical Society 122:5891–5892. DOI: 10.1021/ja000563a
  7. Craik DJ, Fairlie DP, Liras S, Price D (2013). The future of peptide-based drugs. Chemical Biology & Drug Design 81:136–147. DOI: 10.1111/cbdd.12055
  8. Passioura T, Katoh T, Goto Y, Suga H (2014). Selection-based discovery of druglike macrocyclic peptides. Annual Review of Biochemistry 83:727–752. DOI: 10.1146/annurev-biochem-060713-035456